MDGL - NASDAQ

Madrigal Pharmaceuticals, Inc.

MDGL·NASDAQ

$488.15

+7.8%

HealthcareBiotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$11.25B

EPS-12.8500

P/E Ratio-45.32

Earnings Date08/04/2026

mdgl

Free Cash Flow

Last Annual Value

-190.02M

3-Year CAGR

5-Year CAGR

-4%

10-Year CAGR

-10%

Adjust for Inflation

Madrigal Pharmaceuticals, Inc. Competitors Analysis of Free Cash Flow

MDGL · NASDAQ

Company	Free Cash Flow	CAGR 3Y	CAGR 5Y	CAGR 10Y
Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL	-190.02M	N/A	N/A	N/A
Rhythm Pharmaceuticals, Inc. NASDAQ:RYTM	-116.63M	N/A	N/A	N/A
Caris Life Sciences, Inc. NASDAQ:CAI	66.89M	N/A	N/A	N/A
Atrium Therapeutics, Inc. NASDAQ:RNA	-42.57M	N/A	N/A	N/A
Moderna, Inc. NASDAQ:MRNA	-2.06B	N/A	N/A	N/A
Exelixis, Inc. NASDAQ:EXEL	844.34M	70.5%	20.2%	15.2%
Baxter International Inc. NYSE:BAX	323.00M	-37.0%	-26.7%	-10.1%
Jazz Pharmaceuticals plc NASDAQ:JAZZ	1.30B	6.7%	12.1%	12.2%
BioMarin Pharmaceutical Inc. NASDAQ:BMRN	724.96M	126.3%	31.4%	N/A
Bio-Techne Corporation NASDAQ:TECH	256.55M	5.9%	-3.6%	7.3%

Madrigal Pharmaceuticals, Inc. Fair Value Envelope

MDGL · NASDAQ

Our analysis suggests that MDGL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $488.15, this represents a potential HIDDEN relative to our calculated worth for Madrigal Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $488.15

Related Guides

Blog Categories

Continue your MDGL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.